Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FFBS1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $63,175.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The delivery order, issued on December 19, 2025, with an ultimate completion date of January 13, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. MACI (matrix-applied characterized autologous mesenchymal cells) implants are specialized surgical products used for cartilage repair and regeneration, representing the type of advanced medical consumables that DMS Pharmaceutical Group supplies to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036. The PPV-G GEN V program, part of a broader $30.3 billion acquisition strategy, authorizes the issuance of delivery orders for pharmaceutical products and medical consumables to support military healthcare operations globally. DMS Pharmaceutical Group's established performance across multiple product categories and therapeutic areas demonstrates its capability to fulfill the specialized pharmaceutical and medical supply requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FFBS1?
SPE2DR26FFBS1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FFBS1 worth?
The government has obligated $63,176 on SPE2DR26FFBS1.
Is contract SPE2DR26FFBS1 an order under another contract?
Yes. SPE2DR26FFBS1 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBS1 competed?
The extent of competition for SPE2DR26FFBS1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award